Ibutilide in rapid conversion of atrial flutter in octogenarians

Drugs and Aging

Volumn 19, Issue 10, 2002, Pages 787-791

  Antonicelli, Roberto ^a   Testarmata, Paolo ^a   Recanatini, Andrea ^b  

^a INRCA   (Italy)

^b UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IBUTILIDE; ANTIARRHYTHMIC AGENT; SULFONAMIDE;

AGED; ARTICLE; CARDIOVERSION; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART VENTRICLE TACHYCARDIA; HUMAN; MALE; PRIORITY JOURNAL; SINUS RHYTHM; TORSADE DES POINTES; TREATMENT OUTCOME; ELECTROCARDIOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY;

AGED; AGED, 80 AND OVER; ANTI-ARRHYTHMIA AGENTS; ATRIAL FLUTTER; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; SULFONAMIDES; TREATMENT OUTCOME;

EID: 0036417355     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200219100-00007     Document Type: Article

References (25)

1. Olshansky B, Okumura K, Hess PG, et al. Demonstration of an area of slow conduction in human atrial flutter. J Am Coll Cardiol 1990; 16: 1639-48
2. Olgin JE, Kalman JM, Fitzpatrick A, et al. Role of right atrial endocardial structures as barriers to conduction during human type I atrial flutter. Circulation 1995; 92: 1839-48
3. Kalman JM, Olgin JE, Saxon LA, et al. Activation and entrainment mapping defines the tricuspid annulus as the anteriorbarrier in atrial flutter. Circulation 1996; 94: 398-406
4. Nakagawa H, Lazzara R, Khastir T, et al. Role of the tricuspid annulus and the Eustachian valve/ridge on atrial flutter: Relevance to catheter ablation of the septal isthmus and a new technique for rapid identification of ablation success. Circulation 1996; 94: 407-24
5. Granada J, Uribe W, Chyou P-H, et al. Incidence and predictors of atrial flutter in the general population. J Am Coll Cardiol 2000; 36: 2242-6
6. Waldo A. Treatment of atrial flutter. Heart 2000; 84 (2): 227-32
7. Biblo LA, Yuan Z, Quan KJ, et al. Risk of stroke in patients with atrial flutter. Am J Cardiol 2001; 87 (3): 346-9
8. Manning WJ, Silvermann DI, Katz SE, et al. Temporal dependance of the return of atrial mechanical function on the mode of cardioversion of atrial fibrillation to sinus rhythm. Am J Cardiol 1995; 75: 624-6
9. Campbell RWF. Pharmacologic therapy of atrial flutter. J Cardiovasc Electrophysiol 1996; 7: 1008-12
10. Hou ZY, Chang MS, Chen CY, et al. Acute treatment of recent-onset atrial fibrillation and flutter with a tailored dosing regimen of intravenous amiodarone: A randomised, digoxin-controlled study. Eur Heart J 1995; 16: 521-8
11. Murray KT. Ibutilide. Circulation 1998; 97: 493-9
12. Stambler BS, Wood MA, Ellenbogen KA, et al. Efficacy and safety of repeated Intravenous doses of ibutilide for rapid conversion of atrial flutter or fibrillation. Circulation 1996; 94: 1613-21
13. Abi-Mansour P, Carberry PA, McCowart RJ, et al. Conversion efficacy and safety of repeated dose of ibutilide in patients with atrial flutter and atrial fibrillation. Am Heart J 1998; 136: 632-42
14. Ellenbogen KA, Stambler BS, Wood MA, et al. Efficacy of intravenous doses of ibutilide for rapid termination of atrial fibrillation or flutter: A dose response study. J Am Coll Cardiol 1996; 28: 130-6
15. Rogers KC, Wolfe DA. Ibutilide: A class III rapidly acting antidysrhythmic for atrial fibrillation or atrial flutter. J Emerg Med 2001; 20 (1): 67-71
16. Antonicelli R, Testarmata P, Recanatini A. Efficacy and tolerability of ibutilide in rapid conversion of atrial flutter in very elderly [abstract]. Eur Heart J 2001; 22 Suppl.: 559
17. Varriale P, Sedighi A. Acute management of atrial fibrillation and atrial flutter in the critical care unit: Should it be ibutilide? Clin Cardiol 2000; 23 (4): 256-8
18. Priori SG, Aliot E, Blomstrom-Lundqvist C, et al. Task force on sudden cardiac death of the European Society of Cardiology. Eur Heart J 2000; 22 (16): 1374-450
19. Sobel RM, Dhruva NN. Termination of acute wide complex atrial fibrillation with ibutilide. Am J Emerg Med 2000; 18 (4): 462-4
20. Zaqqa M, Afshar H, Rasekh A, et al. Predictors of conversion to sinus rhythm using ibutilide for atrial fibrillation or flutter. Am J Cardiol 2000; 85: 112-4
21. Singh SN, Zoble RG, Yellen L, et al. Efficacy and safety of oral dofetilide in converting and to maintaining sinus rhythm in patients with chronic atrial fibrillation or flutter: The Symptomatic Atrial Fibrillation Investigative Research on Dofetilide (SAFIRE-D) study. Circulation 2000; 102: 2385-90
22. Kowey PR, Vanderlugt JT, Luderer JR. Safety and risk/benefit analysis of ibutilide for acute cardioversion of atrial fibrillation/flutter. Am J Cardiol 1996; 78 (8A): 46-52
23. Foster RH, Wilde MI, Markham A. Ibutilide: A review of its pharmacological properties and clinical potential in acute management of atrial flutter and fibrillation. Drugs 1997; 54: 312-30
24. Makkar RR, Fromm BS, Steinmann RT, et al. Female gender as a risk factor for torsade de pointes associated with cardiovascular drugs. JAMA 1993; 270: 2590-7
25. DomanovitsH, Schillinger M, Thoenissen J, et al. Termination of recent onset atrial fibrillation/flutter in the emergency department: A sequential approach with intravenous ibutilide and external electrical cardioversion. Resuscitation 2000; 45 (3): 181-6